| Title of the study |
|
Name of the Principal Investigator |
| |
|
|
Pharmacokinetic drug-drug interactions between first line anti-TB and anti-diabetic drugs
|
|
Dr. A.K. Hemanth Kumar |
Pharmacokinetics of second-line anti-TB drugs in children and adolescents with MDR TB
|
|
Dr. A.K. Hemanth Kumar |
Bioavailability of fixed dose combination of first line anti-TB drugs in patients with pulmonary tuberculosis
|
|
Dr. A.K. Hemanth Kumar |
Molecular cloning and characterization of full length infectious Transmitted/Founder HIV-1 viruses
|
|
Dr. Luke E. Hanna
|
Identification of broadly neutralizing antibodies against HIV
|
|
Dr. Luke E. Hanna
|
Inflammation and aging in HIV-infected individuals on long term antiretroviral therapy
|
|
Dr. Luke E. Hanna
|
Identification of biomarkers that can predict progression from Latent Tuberculosis Infection to active TB disease
|
|
Dr. Luke E. Hanna
|
National HIV Cohort Program – Cohorts of HIV Resistance and Progression in Indian Children and Adults (CoHRPICA)
|
|
Dr. Luke E. Hanna
|
Impact of malnutrition on immune responses to tuberculosis in Indian children
|
|
Dr. Aishwarya Venkataraman
|
Development and validation of a diagnostic kit for early detection of Human Papilloma Virus (HPV) infection in cervical cancer
|
|
Dr. N. Sudhakar
|
Latent class analysis of health related quality of life of TB patients during & post treatment in a Longitudinal Design
|
|
Dr. M. Vasantha
|
Development of a Database of Clinical Study X-rays at NIRT, Chennai
|
|
Dr. C. Ponnuraja
|
HTA for implementation of cell counters for referral of suspected dengue cases at PHC settings
|
|
Dr. M. Muniyandi
|
The Economic evaluation of standardised treatment regimens of anti-TB drugs for patients with MDR-TB (STREAM stage-II trial)
|
|
Dr. M. Muniyandi
|
Social network analysis as a tool to improve active case finding at community level in Chennai
|
|
Dr. N. Karikalan
|
Measuring the socio-economic risk-benefits & health related quality of life changes associated with TB disease disclosure
|
|
Dr. N. Karikalan
|
Early bactericidal activity of anti-tuberculosis drugs
|
|
Dr.K.R. Uma Devi
|
Protecting and improving public health globally: Building laboratory, surveillance and workforce capacity to detect, respond to, and prevent drug resistant tuberculosis in India
|
|
Dr.K.R. Uma Devi
|
Identification of the latent tuberculosis specific marker by the immunoproteomic analysis of the cell wall and membrane proteins of M. tuberculosis.
|
|
Dr.K.R. Uma Devi
|
Accurate, Rapid, Robust and Economical diagnostic technologies for Tuberculosis: ARREST-TB
|
|
Dr.K.R. Uma Devi
|
Crohn's disease in India: A multicenter study from a country where intestinal tuberculosis as well as Johne’s disease is endemic
|
|
Dr.P.Kannan
|
Studies on epigenome wide alterations in alveolar macrophages during M. tuberculosis infections in guinea pig pulmonary tuberculosis model
|
|
Dr.P.Kannan
|
Whole Genome Sequencing and Transcriptome analysis of M. tuberculosis clinical isolates from Bovine and Human Origin
|
|
Dr.P.Kannan
|
Identification of Mycobacterium tuberculosis complex (MTBC) organisms in the lymph node samples of slaughtered cattle in Chennai
|
|
Dr.P.Kannan
|
Dereplication guided bio-prospecting of cyclic lipopeptides from marine Bacillus sp. for inhibition of M. tuberculosis
|
|
DR. P.Kannan
Mentor for the project ;
Dr Sagarika Devi- PI for the project |
Systems biology and immunology of the effect of tuberculosis chemoprophylaxis in HIV infection
|
|
Dr. Syed Hissar
and
Dr. Pavan Kumar
|
An open label, three arm, pragmatic, randomized controlled pilot study to determine the protective effect of Kabha sura kudineer (KSK)/ Nilavembu kudineer (NVK) in preventing COVID19 symptoms compared to standard Vitamin C-Zinc supplementation and to examine immune responses among healthcare workers.
|
|
Dr. Pavan Kumar
and
Dr. Subash Babu
|
Identification of tuberculosis specific biomarkers in children by the Proteomic analysis of urine.
|
|
Dr.D.Anbarasu
and
Dr. Syed Hissar
|
Molecular Analysis of monocyte
subsets in humans infected with
Mycobacterium tuberculosis
|
|
Dr.Ramalingam B
|
Attenuated mycobacteria based vaccine against tuberculosis with a novel strategy for T cell priming
|
|
Dr.K.R. Uma Devi
|
CRISPR mediated platform for diagnosis and rapid detection of drug resistance pattern in M. tuberculosis.
|
|
Dr.K.R. Uma Devi
|
Functional characterization of oxidoreductases of M. tuberculosis
|
|
Dr.P.Kannan
|
Study on Mutations Associated with Pyrazinamide Resistance in M. tuberculosis
|
|
Dr.P.Kannan
|
A cross sectional study of the systems immunology and viral diversity of SARS-CoV2 infection, COVID-19 disease and Multisystem Inflammatory Syndrome in children
|
|
Dr. Pavan Kumar
and
Dr. Subash Babu
|
Characterization and Durability of COVID-19 vaccine induced immune responses in healthcare/frontline workers
|
|
Dr. Pavan Kumar
and
Dr. Banu Rekha
|
Humoral and cellular immune response among recovered COVID-19 patients: A cross-sectional study, Tiruvallur district, Chennai Corporation, Tamil Nadu, India, 2020
|
|
Dr. Pavan Kumar (Co PI)
|
Role of neutralizing antibodies and inflammatory biomarkers in children with Paediatric Inflammatory Multisystem Syndrome - Temporally Associated with SARS-CoV-2 (PIMS-TS)
|
|
Dr. Pavan Kumar (Co PI)
|
Regional Prospective Observational Research in Tuberculosis (RePORT) - Phase 2
|
|
Dr. Pavan Kumar (Co PI)
|
CYP2R1 gene polymorphisms in pulmonary tuberculosis
|
|
Dr. Ramalingam B
&
Dr. Harishanker |
Immunomodulation of Autophagy by Vitamin D3 in macrophages Infected with Mycobacterium tuberculosis
|
|
Dr. Ramalingam B
|
Molecular and immune profiling in adults affected with COVID-19 disease
|
|
Dr. N.Sudhakar |
| |
|
|
.
